CO2019014350A2 - Formulaciones farmacéuticas de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1­metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y las sales de ellas - Google Patents

Formulaciones farmacéuticas de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1­metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y las sales de ellas

Info

Publication number
CO2019014350A2
CO2019014350A2 CONC2019/0014350A CO2019014350A CO2019014350A2 CO 2019014350 A2 CO2019014350 A2 CO 2019014350A2 CO 2019014350 A CO2019014350 A CO 2019014350A CO 2019014350 A2 CO2019014350 A2 CO 2019014350A2
Authority
CO
Colombia
Prior art keywords
indol
pyrimidin
acrylamide
dimethylamino
ethoxy
Prior art date
Application number
CONC2019/0014350A
Other languages
English (en)
Inventor
Michael Nicholas Greco
Michael John Costanzo
Jirong Peng
Michael Alan Green
Don Zhang
Victoria Lynn Wilde
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of CO2019014350A2 publication Critical patent/CO2019014350A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan una formulación farmacéutica de N-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1-metil-1H-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida (compuesto 1), en particular la sal del ácido metanosulfónico de ella y métodos para usar la formulación farmacéutica para el tratamiento o la prevención de enfermedades o afecciones médicas mediadas a través de formas mutadas del receptor del factor de crecimiento epidérmico (EGFR), tales como diversos cánceres
CONC2019/0014350A 2017-06-16 2019-12-18 Formulaciones farmacéuticas de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1­metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y las sales de ellas CO2019014350A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762521007P 2017-06-16 2017-06-16
PCT/US2018/037744 WO2018232235A1 (en) 2017-06-16 2018-06-15 Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof

Publications (1)

Publication Number Publication Date
CO2019014350A2 true CO2019014350A2 (es) 2020-04-24

Family

ID=64660336

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0014350A CO2019014350A2 (es) 2017-06-16 2019-12-18 Formulaciones farmacéuticas de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1­metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y las sales de ellas

Country Status (16)

Country Link
US (2) US11180478B2 (es)
EP (1) EP3638241B1 (es)
JP (2) JP7045726B2 (es)
KR (1) KR20200016969A (es)
CN (1) CN110799191B (es)
AU (1) AU2018283289B2 (es)
BR (1) BR112019026483A2 (es)
CA (1) CA3067044A1 (es)
CO (1) CO2019014350A2 (es)
EA (1) EA201992744A1 (es)
IL (1) IL271220A (es)
MX (1) MX2019015177A (es)
PH (1) PH12019502830A1 (es)
SG (1) SG11201911859QA (es)
TW (1) TW201904577A (es)
WO (1) WO2018232235A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210028191A (ko) * 2018-06-18 2021-03-11 유씨비 바이오파마 에스알엘 암을 예방 및 치료하기 위한 gremlin-1 길항제
CN110898026A (zh) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 包含bpi-7711的药用组合物及其制备方法
CN111100117B (zh) * 2019-12-18 2021-02-19 上海倍而达药业有限公司 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102295643B (zh) 2002-01-22 2013-12-04 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
WO2007049294A1 (en) 2005-10-28 2007-05-03 Arch Pharmalabs Limited An improved process for preparation of gemcitabine hydrochloride.
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
EP2184984A4 (en) * 2007-07-30 2013-07-24 Ardea Biosciences Inc N- (ARYLAMINO) ARYLSULFONAMIDE DERIVATIVES COMPRISING POLYMORPHS AS MEK INHIBITORS AND COMPOSITIONS, METHODS OF USE AND PREPARATION METHODS THEREOF
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EA029990B1 (ru) 2009-11-27 2018-06-29 Джензим Корпорэйшн Способы лечения ингибиторами глюкозилцерамидсинтазы
MX357614B (es) 2010-04-12 2018-07-17 Supernus Pharmaceuticals Inc Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX336741B (es) * 2010-07-16 2016-01-29 Exelixis Inc Composiciones farmaceuticas de moduladores de c-met.
DK3333161T3 (da) 2011-07-27 2020-05-18 Astrazeneca Ab 2-(2,4,5-substitueret anilin)-pyrimidinderivater som egfr-modulatorer, der er anvendelige til behandling af cancer
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN112375067B (zh) * 2014-12-11 2024-03-15 贝达医药公司 取代的2-苯胺基嘧啶衍生物及其作为表皮生长因子受体调节剂
CN104961731A (zh) 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
CN104910049B (zh) 2015-06-16 2016-06-29 苏州明锐医药科技有限公司 Azd9291中间体及其制备方法
AU2017264839B2 (en) 2016-05-11 2021-08-05 Beta Pharma, Inc. 2-Anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
WO2017218892A1 (en) * 2016-06-17 2017-12-21 Beta Pharma, Inc. Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

Also Published As

Publication number Publication date
JP2020523376A (ja) 2020-08-06
PH12019502830A1 (en) 2020-12-07
EA201992744A1 (ru) 2020-05-27
IL271220A (en) 2020-01-30
SG11201911859QA (en) 2020-01-30
KR20200016969A (ko) 2020-02-17
JP7045726B2 (ja) 2022-04-01
US20220153726A1 (en) 2022-05-19
CA3067044A1 (en) 2018-12-20
AU2018283289B2 (en) 2021-03-25
EP3638241B1 (en) 2022-05-25
WO2018232235A1 (en) 2018-12-20
MX2019015177A (es) 2020-02-07
JP2022058492A (ja) 2022-04-12
TW201904577A (zh) 2019-02-01
US20200131152A1 (en) 2020-04-30
EP3638241A1 (en) 2020-04-22
BR112019026483A2 (pt) 2020-07-14
EP3638241A4 (en) 2020-10-07
AU2018283289A1 (en) 2020-01-02
CN110799191A (zh) 2020-02-14
US11180478B2 (en) 2021-11-23
CN110799191B (zh) 2023-05-26

Similar Documents

Publication Publication Date Title
CO2019014350A2 (es) Formulaciones farmacéuticas de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1­metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y las sales de ellas
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
CO2017008862A2 (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
CY1123604T1 (el) Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4-μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου
CL2018001830A1 (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
PE20191557A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CO2018013416A2 (es) Sales farmacéuticas de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(l-metil-ih-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida y formas cristalinas de las mismas
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
AR096462A1 (es) 4-(5-(4-CLOROFENIL)-2-(2-CICLOPROPILACETIL)-1,4-DIMETIL-1H-PIRROL-3-IL)BENECENSULFONAMIDA COMO MODULADOR DE a7 nAChR
CO6680652A2 (es) Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina
CO2017007691A2 (es) Inhibidores de la β-secretasa derivados de la 5-amino-3-(5-(3-isoxazol-5-il)-3-(fluorometil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina o 5-amino-3-(5-(1h-1,2,3-triazol-4-il)-2-fluorofenil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina composiciones que los comprenden y métodos de elaboración
MY197663A (en) Pharmaceutical formulation
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
BR112018013356A2 (pt) sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica
PL421685A1 (pl) Nowe zastosowanie 2-izotiocyjanianoetylobenzenu w terapii choroby Huntingtona
AR108090A1 (es) Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
PE20170472A1 (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina